LEVEMIR FLEXPEN
Clinical safety rating
cautionComprehensive clinical and safety monograph for LEVEMIR FLEXPEN (LEVEMIR FLEXPEN).
Long-acting insulin analog that activates insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis.
| Metabolism | Metabolized via insulin-degrading enzyme (IDE); less susceptible to hepatic degradation. |
| Excretion | Renal (30-40% unchanged), remainder hepatically metabolized and excreted in bile/feces; negligible fecal elimination of parent drug. |
| Half-life | Terminal elimination half-life approximately 5-7 hours in children (<6 years: 3-4 hours); provides flat, prolonged pharmacokinetic profile over 24 hours with no pronounced peak. |
| Protein binding | >98% bound to albumin. |
| Volume of Distribution | 0.12 L/kg (intravenous); indicates distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous: approximately 60-65% (range 44-81% depending on injection site). |
| Onset of Action | Subcutaneous: 3-4 hours after injection. |
| Duration of Action | Up to 24 hours (range 16-24 hours); requires once-daily fixed dosing; less pronounced peak than NPH. |
| Molecular Weight | 5916 |
Subcutaneous injection. Initial dose: 0.2-0.5 units/kg/day once daily or divided into two doses. Titrate by 2-10 units once or twice weekly based on glycemic control. Maximum dose not defined.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required, but increased risk of hypoglycemia. Monitor glucose closely; dose reduction may be necessary. |
| Liver impairment | No specific Child-Pugh based guidelines. Use with caution; dose adjustment may be needed due to altered glucose metabolism. |
| Pediatric use | Subcutaneous injection. For type 1 diabetes: initial 0.1-0.2 units/kg/day once daily or divided. For type 2 diabetes: initial 0.2-0.5 units/kg/day. Titrate based on glycemic response. |
| Geriatric use | Start at lower doses (e.g., 0.1-0.2 units/kg/day) due to increased risk of hypoglycemia. Titrate cautiously, monitor renal function and glucose closely. |
| 1st trimester | Insulin detemir does not cross the placenta in significant amounts. No known teratogenic risk. Maintain glycemic control to prevent congenital anomalies. |
| 2nd trimester | Insulin requirements may increase due to placental hormones. Monitor glucose closely. Insulin detemir is safe for use. |
| 3rd trimester | Insulin requirements may increase further. Monitor for hypoglycemia. Safe for use in gestational diabetes and preexisting diabetes. |
Clinical note
Comprehensive clinical and safety monograph for LEVEMIR FLEXPEN (LEVEMIR FLEXPEN).
| Placental transfer | Minimal placental transfer due to high molecular weight and binding to albumin. Less than 1% of maternal dose reaches fetal circulation. |
| Breastfeeding | Insulin detemir is a large protein molecule unlikely to be excreted into breast milk in significant amounts. No adverse effects on the breastfed infant reported. Use caution in mothers with diabetes; maintain glycemic control. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Insulin detemir (Levemir) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. In humans, there is no evidence of increased risk of fetal malformations; however, poor glycemic control is associated with fetal risks including congenital anomalies, macrosomia, and neonatal hypoglycemia. Insulin detemir does not cross the placenta in significant amounts. Close monitoring of glucose control is recommended throughout pregnancy. |
| Fetal Monitoring | Monitor maternal blood glucose levels frequently, including fasting and postprandial glucose. Assess hemoglobin A1c periodically. During labor and delivery, monitor glucose closely to avoid maternal hypoglycemia. Fetal monitoring includes ultrasound for growth and amniotic fluid volume, and fetal non-stress tests or biophysical profiles as indicated. |
| Fertility Effects | Insulin detemir has no known direct effects on fertility. However, uncontrolled diabetes can impair fertility and increase pregnancy complications. Achieving good glycemic control may improve fertility outcomes. |
■ FDA Black Box Warning
Never share a Levemir FlexPen between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
| Serious Effects |
Hypersensitivity to insulin detemir or any excipientsHypoglycemia
| Precautions | Hypoglycemia is the most common adverse reaction, Monitor blood glucose; adjust dose with changes in renal/hepatic function, Exercise caution in patients with hypokalemia or during illness/stress |
| Food/Dietary | No specific food interactions, but meals high in fat may slow absorption and affect glycemic response. Avoid excessive alcohol intake as it can increase risk of hypoglycemia. Consistent carbohydrate intake is recommended for glycemic control. Grapefruit may affect insulin sensitivity but interaction is not well-documented. |
| Clinical Pearls | Levemir is a long-acting insulin analog (detemir) with a duration of action up to 24 hours, often used for basal insulin coverage. It has a lower risk of hypoglycemia compared to NPH insulin due to its more predictable absorption. Do not mix with other insulins in the same syringe. Onset is 3-4 hours, peak is 6-8 hours, duration is up to 24 hours. Dose adjustments are needed in renal or hepatic impairment. Administer once or twice daily; if twice daily, evening dose should be given at bedtime or with the evening meal. Shake the FlexPen gently before use to ensure uniform suspension. |
| Patient Advice | Inject subcutaneously into abdomen, thigh, or upper arm; rotate sites to prevent lipodystrophy. · Do not use if the solution is cloudy or contains particles; it should be clear and colorless. · Store unopened pens in refrigerator at 2-8°C; once in use, keep at room temperature below 30°C and discard after 42 days. · Avoid alcohol consumption as it may increase risk of hypoglycemia. · Do not share your FlexPen with others even if the needle is changed. · Monitor blood glucose regularly and keep a record. · Recognize symptoms of hypoglycemia (sweating, dizziness, confusion) and hyperglycemia (frequent urination, thirst, blurred vision). · Carry a source of fast-acting sugar (e.g., glucose tablets, juice) for hypoglycemia treatment. · Do not use if the insulin has been frozen or exposed to temperatures above 30°C. |
Loading safety data…